logo
Share SHARE
FONT-SIZE Plus   Neg

Chelsea Therapeutics Updates On Northera Regulatory Status, Development Program

Chelsea Therapeutics International Ltd. (CHTP) has received a written response from the U.S. Food and Drug Administration or FDA to its modified proposal for utilizing data from ongoing Study 306B to support its application for marketing approval of Northera in the U.S. In its response, FDA advised Chelsea that, based on the theoretical potential for certain patients from Study 306B to have been unblinded in conjunction with the reporting of 306A data, the FDA cannot be confident that this information did not influence an amendment of the statistical analytic plan, and therefore believes, as presently planned, Study 306B is unlikely to provide sufficient confirmatory evidence to support a Northera Capsules New Drug Application or NDA.

The Advice Letter from the FDA stated "if an analysis of all subjects enrolled in study 306 after [Chelsea] amended the analytic plan demonstrated a statistically significant benefit on the primary endpoint, [FDA] might regard this as a positive trial." However, as this analytic approach seems to exclude at least 109 patients from Study 306B, the FDA further urges that Chelsea 'design and conduct an additional trial to show that droxidopa has a significant and persistent effect' on symptoms of neurogenic orthostatic hypotension.

Based on FDA's feedback, the company is now evaluating several scenarios that may provide the supportive data the FDA is seeking while minimizing any delays to the planned resubmission of its Northera NDA.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Tech companies are joining a growing backlash in Silicon Valley against the cyber presence of neo-Nazis and other hate groups after Charlottesville attack. The companies, including Apple, Facebook and Reddit, are beginning to take action after the tragedy highlighted neo-Nazi communities across the internet. Mortgage rates are continuing to hold at low levels amidst ongoing economic uncertainty, mortgage provider Freddie Mac announced Thursday. The 30-year fixed-rate mortgage averaged 3.89% with an average 0.4 point during the week ending August 17, down from 3.90% in the prior week. It is now just one basis point above its 2017 low. Shares of Infosys Technologies Ltd. were losing around 10 percent in Indian trading on Friday after the Software exporter announced that Vishal Sikka has resigned as the Managing Director and Chief Executive Officer with immediate effect. The company appointed current chief operating officer Pravin Rao as the Interim-Managing Director and Chief Executive Officer.
comments powered by Disqus
Follow RTT